Physician profile
Matthew B Cotant
NPI 1003930215
$16,613.87
in general payments reported to CMS, 2019-2025
78 companies · $3,912 in 2025
The $3,912 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,029 · 2020: $728 · 2021: $777 · 2022: $2,015 · 2023: $3,160 · 2024: $3,993 · 2025: $3,912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,425 · Long Term Medical Supply Or Device Loan: $2,115 · Education: $526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,424.54 |
| Long Term Medical Supply Or Device Loan | $2,114.51 |
| Education | $526.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,143.44 | 2019-2025 | |
| Genentech USA, INC. | $1,133.69 | 2019-2025 | Polivy, Tecentriq, Lunsumio |
| Astrazeneca Pharmaceuticals Lp | $782.20 | 2019-2025 | Tagrisso, Calquence, Lynparza |
| Amgen INC. | $747.67 | 2019-2023 | Kyprolis, Blincyto, Xgeva |
| Astellas Pharma US INC | $622.28 | 2019-2025 | Xtandi, Padcev, Xospata |
| Janssen Biotech, INC. | $601.71 | 2019-2025 | Darzalex, Tecvayli, Rybrevant |
| Pfizer INC. | $572.72 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $557.54 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Merck Sharp & Dohme LLC | $518.94 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Eisai INC. | $399.75 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $383.88 | 2019-2023 | |
| Gilead Sciences, INC. | $370.56 | 2021-2025 | Trodelvy |
| Daiichi Sankyo INC. | $333.40 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Genzyme Corporation | $324.05 | 2019-2025 | |
| Celgene Corporation | $302.14 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
Show all 78 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $294.55 | 2019-2024 | Verzenio, Retevmo, Jaypirca |
| Glaxosmithkline, LLC. | $283.60 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Abbvie INC. | $279.04 | 2019-2025 | |
| Genmab U.S., INC. | $276.04 | 2023-2025 | Epkinly |
| Mirati Therapeutics, INC. | $264.46 | 2023-2024 | Krazati |
| Exelixis INC. | $233.98 | 2021-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $232.46 | 2019-2025 | |
| Emd Serono, INC. | $205.71 | 2019-2025 | Tepmetko |
| Seagen INC. | $195.38 | 2020-2023 | Tukysa, Padcev |
| Amag Pharmaceuticals, INC. | $174.33 | 2019-2021 | |
| Rigel Pharmaceuticals, INC. | $165.58 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Incyte Corporation | $147.40 | 2019-2024 | Jakafi |
| Kite Pharma, INC. | $147.01 | 2020-2025 | Yescarta |
| Array Biopharma INC | $144.79 | 2020-2025 | Braftovi, Mektovi, Tukysa |
| Tersera Therapeutics LLC | $135.73 | 2022-2025 | Zoladex |
| Beigene USA, INC. | $134.71 | 2020-2024 | Brukinsa, Tevimbra |
| Jazz Pharmaceuticals INC. | $134.37 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $133.87 | 2022-2025 | Iclusig, Alunbrig, Vpriv |
| Ipsen Biopharmaceuticals, INC | $115.63 | 2021-2025 | Onivyde, Tazverik, Somatuline Depot |
| Servier Pharmaceuticals LLC | $115.22 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $113.76 | 2021-2025 | Fotivda |
| Stemline Therapeutics INC. | $107.23 | 2023-2025 | Orserdu |
| Pharmaessentia USA Corporation | $96.83 | 2022-2025 | Besremi |
| Taiho Oncology, INC. | $91.94 | 2020-2024 | |
| Agios Pharmaceuticals, INC. | $86.52 | 2023-2024 | Pyrukynd |
| Beone Medicines USA, INC. | $83.45 | 2025 | Brukinsa, Tevimbra |
| Puma Biotechnology, INC. | $81.26 | 2020-2025 | |
| Sobi, INC | $79.54 | 2022-2023 | |
| Geron Corporation | $79.13 | 2025 | Rytelo |
| Regeneron Healthcare Solutions, INC. | $78.83 | 2022-2024 | Libtayo |
| Deciphera Pharmaceuticals INC. | $69.68 | 2020-2025 | Qinlock |
| Acrotech Biopharma INC. | $64.68 | 2023-2025 | Beleodaq |
| Recordati_rare_diseases_inc. | $57.74 | 2024-2025 | Enjaymo, Sylvant |
| Adaptive Biotechnologies Corporation | $57.02 | 2025 | Clonoseq |
| Sumitomo Pharma America, INC. | $55.69 | 2023-2024 | Orgovyx |
| Karyopharm Therapeutics INC. | $55.31 | 2020-2025 | Xpovio |
| Pharmacyclics LLC, An Abbvie Company | $54.59 | 2019-2022 | |
| G1 Therapeutics, INC. | $50.49 | 2021-2023 | Cosela |
| Janssen Pharmaceuticals, INC | $46.36 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $45.91 | 2023-2024 | Ultomiris |
| Syndax Pharmaceuticals, INC. | $45.07 | 2025 | |
| Caris Mpi, INC. | $40.75 | 2025 | Mi Cancer Seek |
| Pharmacosmos Therapeutics INC. | $39.99 | 2024 | Monoferric |
| Iovance Biotherapeutics, INC. | $35.80 | 2025 | Amtagvi |
| Secura Bio, INC. | $30.63 | 2019-2023 | Copiktra |
| Adc Therapeutics America, INC. | $28.81 | 2025 | |
| Apellis Pharmaceuticals, INC. | $28.23 | 2025 | Empaveli |
| Immunocore Limited | $25.94 | 2024 | Kimmtrak |
| Octapharma USA, INC. | $24.62 | 2024 | Octagam Immune Globulin (Human) |
| Myriad Genetic Laboratories, INC. | $23.30 | 2023 | Myrisk |
| Foundation Medicine, INC. | $22.95 | 2019 | |
| Organon LLC | $22.34 | 2023 | Ontruzant |
| Tempus Ai, INC | $22.05 | 2024 | |
| Blue Earth Diagnostics | $19.71 | 2020 | |
| Kyowa Kirin, INC. | $19.63 | 2022 | |
| Morphosys, US INC. | $18.74 | 2023 | Monjuvi |
| Mylan Institutional INC. | $17.68 | 2023 | Ogivri, Fulphila |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.45 | 2025 | |
| Spectrum Pharmaceuticals INC. | $17.25 | 2023 | Rolvedon |
| Myovant Sciences INC. | $13.39 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $12.39 | 2019 | |
| Coherus Oncology, INC. | $12.29 | 2022 | |
| Verastem, INC. | $11.07 | 2019 |
Drugs and devices associated with these payments
Kisqali $2,487Keytruda $317Epkinly $303Krazati $302Venclexta $298Polivy $284Verzenio $209Lenvima $200Tecentriq $188Lunsumio $183Reblozyl $181Darzalex $176Ojjaara $173Trodelvy $169Stivarga $169Vitrakvi $169Columvi $164Imbruvica $155Enhertu $151Tukysa $147Alecensa $147Tecvayli $140Brukinsa $138Scemblix $134Pluvicto $133Opdivo $132Opdualag $127Jevtana $123Zoladex $120Jaypirca $119Retevmo $119Braftovi $118Xtandi $113Orserdu $107Piqray $95.58Cabometyx $92.43Padcev $92.27Mektovi $83.35Tecentriq Hybreza $83.34Datroway $83.31Enjaymo $83.25Nubeqa $79.50Rytelo $79.13Zepzelca $78.63Orgovyx $78.25Idhifa $76.65Yescarta $76.35Rezlidhia $76.29Tavalisse $76.29Tibsovo $71.09Lorbrena $70.83Rybrevant $67.38Tagrisso $65.96Beleodaq $64.68Talvey $62.88Gavreto $62.04Cablivi $60.76Doptelet $60.34Ibrance $60.30Besremi $59.53Blincyto $57.56Kyprolis $57.56Clonoseq $57.02Lonsurf $56.91Inqovi $56.91Fotivda $56.16Libtayo $55.78Lynparza $55.68Welireg $55.17Itovebi $53.67Paxlovid $52.55Onivyde $50.45Tepmetko $50.03Tazverik $49.66Iclusig $48.10Phesgo $47.95Jakafi $47.57Calquence $47.39Jemperli $47.25Zejula $47.25Bosulif $45.97Ultomiris $45.91Pyrukynd $45.15Rozlytrek $43.08Tevimbra $41.12Mi Cancer Seek $40.75Monoferric $39.99Qinlock $39.98Cosela $37.91Injectafer $37.52Amtagvi $35.80Pomalyst $35.12Carvykti $34.36Xofigo $31.65Besponsa $31.25Imfinzi $30.80Zynlonta $28.81Xpovio $28.78Empaveli $28.23Alunbrig $27.53
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Cotant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.